(NASDAQ: BBIO) Bridgebio Pharma's forecast annual revenue growth rate of 39.65% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.74%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.61%.
Bridgebio Pharma's revenue in 2026 is $945,540,000.On average, 25 Wall Street analysts forecast BBIO's revenue for 2026 to be $215,449,664,892, with the lowest BBIO revenue forecast at $184,223,099,537, and the highest BBIO revenue forecast at $253,435,817,382. On average, 24 Wall Street analysts forecast BBIO's revenue for 2027 to be $331,940,532,528, with the lowest BBIO revenue forecast at $283,045,536,246, and the highest BBIO revenue forecast at $384,536,743,668.
In 2028, BBIO is forecast to generate $506,871,634,764 in revenue, with the lowest revenue forecast at $393,302,778,858 and the highest revenue forecast at $738,879,366,126.